GlassScriptPhysician profile
Lee G Razalan
NPI 1780601534
$7,122.52
in general payments reported to CMS, 2019-2025
28 companies · $410 in 2025
The $410 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,311 · 2020: $1,133 · 2021: $1,704 · 2022: $1,038 · 2023: $752 · 2024: $777 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,937.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $835.80 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $786.89 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $783.08 | 2020-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $751.93 | 2021-2025 | |
| Glaxosmithkline, LLC. | $729.02 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $487.84 | 2019-2022 | |
| Amarin Pharma, INC. | $443.85 | 2019-2021 | |
| Lilly USA, LLC | $441.59 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.52 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $256.92 | 2019-2024 | Veozah |
| Exact Sciences Corporation | $244.62 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $179.82 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $154.08 | 2019-2023 | Repatha, Otezla |
| Urovant Sciences INC | $123.77 | 2022 | |
| Abbott Laboratories | $101.70 | 2022-2024 | Freestyle Libre 3 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $101.20 | 2022-2023 | |
| Hikma Pharmaceuticals USA | $71.59 | 2019-2022 | |
| Dexcom, INC. | $64.98 | 2023-2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $51.80 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $33.96 | 2024 | |
| Alexion Pharmaceuticals, INC. | $33.74 | 2024 | Ultomiris |
| Gilead Sciences, INC. | $33.47 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $29.22 | 2022-2023 | Eliquis |
| Sanofi-Aventis U.S. LLC | $22.31 | 2019 | |
| Esperion Therapeutics, INC. | $21.48 | 2021 | |
| Horizon Therapeutics Plc | $19.24 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.86 | 2022 | |
| Sunovion Pharmaceuticals INC. | $14.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Razalan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.